ClinicalTrials.gg
RecruitingNCT06278909Updated Apr 8, 2025

Trigeminal Nerve Stimulation in Treatment-resistant Generalized Anxiety Disorder: a Feasibility Study

An interventional study of Trigeminal Nerve Stimulation in Generalized Anxiety Disorder, sponsored by Dr. Rafael Freire. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Dr. Rafael Freire · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Generalized Anxiety Disorder with a site in Canada — 7 open to participants now, 11 under way, none of them phase 3. Generalized Anxiety Disorder · Canada.

Planned enrollment
37th of 45
10 · median 63
Started
2024
with 2 others
No phase
32 of 50
4 open now
Primary completion
2026-03
later than 6 of 10 live
Registered
47th of 50
by date
Lead sponsor
2 of 50
Dr. Rafael Freire

Among the 50 studies in Generalized Anxiety Disorder with a site in Canada, this one is the 37th largest by planned enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2024, is one of 32 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 47th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

7 of the 50 studies in Generalized Anxiety Disorder with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 88 Generalized Anxiety Disorder studies recruiting now, 32 (36%) set no upper age limit and 54 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Generalized Anxiety Disorder with a site in Canada, or all of them as a file.
02

Study summary

This is a feasibility study for trigeminal nerve stimulation (TNS) in patients with treatment-resistant generalized anxiety disorder (TR-GAD). Ten participants will receive TNS for 8 weeks as an augmentation strategy to pharmacological treatment for generalized anxiety disorder (GAD).

  • The primary objective is to ascertain if TNS is a safe and well-tolerated treatment for patients with TR-GAD.
  • The secondary objective will be to monitor changes in GAD symptom severity throughout the study.

Results from this study will inform a randomized controlled trial to be conducted in the future.

03

Conditions studied

  • Generalized Anxiety Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the , Fifth Edition (DSM5) criteria for generalized anxiety disorder.
  • Subjects on a stable dose of an selective serotonin reuptake inhibitor (SSRI) or serotonin and noradrenaline reuptake inhibitor (SNRI) for at least 8 weeks.
  • Treatment-resistant - treatment resistance will be defined as lack of response to at least two drugs, from two different classes of drugs considered or second-line for GAD. Only trials lasting at least 8 weeks, and with at least the minimum effective dose of the given medication will be considered failed trials.

Exclusion criteria

Exclusion Criteria:

  • Moderate to severe major depressive disorder
  • Moderate to high suicidality
  • Diagnosis of obsessive compulsive disorder (OCD), PTSD, bipolar disorder, schizophrenia, schizoaffective disorder, personality disorders, substance use disorders, intellectual disabilities and dementia or other neurological diseases including trigeminal neuralgia
  • Pregnant or breastfeeding women
  • Participants who are experiencing seizures
  • Implanted vagal nerve stimulation (VNS) or other electrical devices
  • Participants who are already undergoing transcutaneous electrical nerve stimulation
  • Consumption of cannabis, any cannabis by-products, illicit drugs, or alcohol above 3 drinks per week
  • Consumption of natural health products that may affect anxiety or depression symptoms
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Active stimulation

    Trigeminal nerve stimulation will occur by placement of electrodes (1.25" silver electrodes Bio-Flex BF4, Biotens/Vermed, Buffalo, New York, USA) bilaterally on the V1 branches of the trigeminal nerve (CNV) located on the forehead. Current will be generated from the EMS 7500 stimulator (TENS Products, Inc., Granby, CO) (Class II medical device) and will be set to a level that is clearly perceptible by each patient (i.e. tingling sensation) but not uncomfortable or painful. Current level will be determined for each patient at baseline and will likely be between 4-6 milliampere (mA). Active stimulation will occur at 120 Hz with a 250 μs pulse width and with a duty cycle of 30 seconds on to 30 seconds off.

    Device: Trigeminal Nerve Stimulation

Interventions

  • DeviceTrigeminal Nerve Stimulation

    Active trigeminal nerve stimulation

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events

    Monitor participants for treatment-emergent adverse events and serious adverse events.

    Time frame: Throughout the study, 8 weeks

  2. Incidence of treatment-emergent side effects measured with the NSEC

    Monitor participants for minor treatment-emergent side effects measured with the Neurostimulation Side-Effect Checklist (NSEC). NSEC is a list of 31 possible side effects from neurostimulation or from antidepressants. Each item is rated from 0 (absent) to 3 (severe).

    Time frame: Baseline visit, 4-week visit and 8-week visit.

  3. Response to treatment defined by CGI-I score below 3

    Response to treatment, which will be defined as a score of 1 or 2 on the Clinical Global Impression - Improvement (CGI-I) scale. CGI-I is a clinician administered one-item clinical scale rated from 1 (very much improved) to 7 (very much worse). Not assessed would confer score 0.

    Time frame: 4-week visit and 8-week visit.

Secondary outcomes

  1. Remission defined by CGI-S score below 3

    Remission will be defined as a score of 1 or 2 on the Clinical Global Impression - Severity (CGI-S) scale. CGI-S is a clinician administered one-item clinical scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Not assessed would confer score 0.

    Time frame: 4-week visit and 8-week visit.

  2. Change in anxiety severity measured by CGI-S

    Changes in scores for CGI-S by comparing the scores in each visit. CGI-S is a clinician administered one-item clinical scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Not assessed would confer score 0.

    Time frame: Baseline visit, 4-week visit and 8-week visit.

  3. Change of anxiety symptoms measured with GAD-7

    Changes in scores for Generalized Anxiety Disorder 7-item scale (GAD-7) by comparing the scores in each visit. GAD-7 is a self-rated 7-item scale, each item is rated from 0 (not at all) to 3 (nearly every day).

    Time frame: Baseline visit, 4-week visit and 8-week visit.

  4. Change of anxiety symptoms measured with PSWQ

    Changes in scores for Penn State Worry Questionnaire (PSWQ) by comparing the scores in each visit. PSWQ is a self-rated 16-item scale, each item is rated from 1 (not at all typical of me) to 5 (very typical of me).

    Time frame: Baseline visit, 4-week visit and 8-week visit.

  5. Change of anxiety symptoms measured with BAI

    Changes in scores for Beck Anxiety Inventory (BAI) by comparing the scores in each visit. BAI is a self-rated 21-item scale, each item is rated from 0 (not at all) to 3 (severely - it bothered me a lot).

    Time frame: Baseline visit, 4-week visit and 8-week visit.

07

Study locations

1 of 1 sites recruiting
  • Kingston Health Sciences Centre
    Kingston, Ontario, Canada
    Recruiting
    • Yan Deng · Contactyan.deng@queensu.ca · +1-613-548-7839
    • Rafael Freire, MD PhD · Principal investigator
    • Elisa Brietzke, MD PhD · Sub investigator
    • Claudio Soares, MD PhD · Sub investigator
08

References and documents

Publications

  • Cook IA, Abrams M, Leuchter AF. Trigeminal Nerve Stimulation for Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder. Neuromodulation. 2016 Apr;19(3):299-305. doi: 10.1111/ner.12399. Epub 2016 Jan 28. PubMed 26818103 ↗
  • Cook IA, Schrader LM, Degiorgio CM, Miller PR, Maremont ER, Leuchter AF. Trigeminal nerve stimulation in major depressive disorder: acute outcomes in an open pilot study. Epilepsy Behav. 2013 Aug;28(2):221-6. doi: 10.1016/j.yebeh.2013.05.008. Epub 2013 Jun 14. PubMed 23773978 ↗
  • Freire RC, Cabrera-Abreu C, Milev R. Neurostimulation in Anxiety Disorders, Post-traumatic Stress Disorder, and Obsessive-Compulsive Disorder. Adv Exp Med Biol. 2020;1191:331-346. doi: 10.1007/978-981-32-9705-0_18. PubMed 32002936 ↗
  • Trevizol AP, Shiozawa P, Sato IA, Calfat EL, Alberto RL, Cook IA, Medeiros HH, Cordeiro Q. Trigeminal Nerve Stimulation (TNS) for Generalized Anxiety Disorder: A Case Study. Brain Stimul. 2015 May-Jun;8(3):659-60. doi: 10.1016/j.brs.2014.12.009. Epub 2014 Dec 31. No abstract available. PubMed 25650095 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Mar 2026, 25 months after the start.

Of 176 non-industry interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 25 months is below that.

Counting every sponsor, half of 185 studies reached it within 28 months; a quarter within 15 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2024
First posted
Feb 26, 2024
StartActual
Jan 18, 2024
Primary completionEst.
Mar 1, 2026
CompletionEst.
Apr 1, 2026
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06278909
Lead sponsor
Dr. Rafael Freire
Responsible party
Dr. Rafael Freire (Associate Professor, Department of Psychiatry, Queen's University) — Sponsor-investigator
First posted
Feb 26, 2024
Start date
Jan 18, 2024
Primary completion
Mar 1, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Apr 8, 2025

Study contacts

Yan Deng
Contact
yan.deng@queensu.ca
+1 613-548-7839
Rafael Freire, MD PhD
Contact
rafael.freire@queensu.ca
+1 613-548-7839
Rafael Freire, MD PhD
principal investigator · Department of Psychiatry, Queen's University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion